ContinueThe first treatment for the underlying cause of Duchenne muscular dystrophy
SOUTH PLAINFIELD, NJ – May 23, 2014 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for…
Added by PPMD on May 23, 2014 at 9:30am — No Comments
Added by PPMD on May 22, 2014 at 8:00pm — No Comments
Santhera reported positive results today from Catena®/Raxone® in their Phase III Duchenne trial. These results are supported by additional respiratory function data. By including pulmonary…
Added by PPMD on May 22, 2014 at 1:00pm — No Comments
In the first study of a utrophin up-regulating drug in Duchenne, British biotech company Summit PLC reports that its drug SMT C1100 showed a good safety profile in twelve boys with Duchenne. Plasma levels of the drug were variable and the company speculates that diet and the course of the disease may be the cause.
The preliminary trial data will be reviewed…
ContinueAdded by PPMD on May 21, 2014 at 9:00am — No Comments
Since being placed on clinical hold in December, Halo has generated additional data from the HT-100 clinical program and completed several toxicology studies, and provided this information to…
A recent PPMD-funded study at Cedars Sinai Medical Center in Los Angeles (published in the May 7, 2014, online issue of Neurology®) demonstrates that those with Duchenne have impaired circulation in their muscles, which may contribute to muscle weakness, and that the approved vasodilator tadalafil can restore that circulation to normal levels. …
ContinueAdded by PPMD on May 7, 2014 at 4:00pm — No Comments
2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2019 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service